Jefferies (NYSE:JEF) analyst Peter Welford maintained a Buy rating on Sanofi (NASDAQ:SNY) on Monday, setting a price target of EUR110, which is approximately 27.73% above the present share price of $100.5.
Welford expects Sanofi to post earnings per share (EPS) of $6.06 for the third quarter of 2020.
The current consensus among 11 TipRanks analysts is for a Moderate Buy rating of shares in Sanofi, with an average price target of $120.31.
The analysts price targets range from a high of $134.21 to a low of $99.2.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $8.44 billion and a net profit of $1.55 billion. The company’s market cap is $128.15 billion.
According to TipRanks.com, Jefferies analyst Peter Welford is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 16.9% and a 66.67% success rate.
Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Human Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes & cardiovascular, established prescription products and generics, together with research, development and production activities. This segment also includes all associates whose activities are related to pharmaceuticals. The Consumer Healthcare segment comprises, for all geographical territories, the commercial operations for its Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines. The company was founded in 1973 and is headquartered in Paris, France.